Ravichandran Venkataramani
Keine laufenden Positionen mehr
Profil
Ravichandran Venkataramani was the founder of Vtesse, Inc. which was founded in 2015, where he held the title of Chief Business Officer.
He also held the position of Vice President-Business Development at Genocea Biosciences, Inc. Dr. Venkataramani obtained a doctorate degree from the University of Pennsylvania and an undergraduate degree from the University of Wisconsin.
Ehemalige bekannte Positionen von Ravichandran Venkataramani
Unternehmen | Position | Ende |
---|---|---|
Vtesse, Inc.
Vtesse, Inc. BiotechnologyHealth Technology Vtesse, Inc. provides novel drugs for life-threatening rare diseases. It developed VTS-270, a modified form of cyclodextrin that has been evaluated in preclinical and clinical studies at institutes within the National Institutes of Health (NIH) to treat patients with Niemann-Pick Disease Type C (NPC). The firm is working with the NIH and other leading academic centers to advance clinical study of VTS-270 for NPC, and to conduct pre-clinical discovery and development of other novel drugs for NPC and other LSDs. The company was founded by Ben Machielse in 2015 and is headquartered in Gaithersburg, MD. | Gründer | - |
GENOCEA BIOSCIENCES, INC. | Corporate Officer/Principal | - |
Ausbildung von Ravichandran Venkataramani
University of Wisconsin | Undergraduate Degree |
University of Pennsylvania | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
GENOCEA BIOSCIENCES, INC. | Health Technology |
Private Unternehmen | 1 |
---|---|
Vtesse, Inc.
Vtesse, Inc. BiotechnologyHealth Technology Vtesse, Inc. provides novel drugs for life-threatening rare diseases. It developed VTS-270, a modified form of cyclodextrin that has been evaluated in preclinical and clinical studies at institutes within the National Institutes of Health (NIH) to treat patients with Niemann-Pick Disease Type C (NPC). The firm is working with the NIH and other leading academic centers to advance clinical study of VTS-270 for NPC, and to conduct pre-clinical discovery and development of other novel drugs for NPC and other LSDs. The company was founded by Ben Machielse in 2015 and is headquartered in Gaithersburg, MD. | Health Technology |